Mosaic Immunoengineering (ticker: CPMV) is a pre-revenue clinical-stage biopharmaceutical company focused on identifying, licensing, and developing biological product candidates. The company generates no product revenue and funds operations through external capital raises, including convertible notes. Mosaic completed a reverse merger with Patriot Scientific Corporation, through which it acquired its current structure, and entered a binding term sheet with Oncotelic Therapeutics in April 2024, with a planned issuance of 47,923,322 shares of common stock to Oncotelic as of the 10-K filed April 15, 2026. As of March 31, 2026, the company had 7,242,137 shares of common stock outstanding. Mosaic holds no internal manufacturing infrastructure and would rely on third-party contract development and manufacturing organizations for any future clinical or commercial production. Case Western Reserve University holds 100% of the outstanding Series B Preferred Stock and is a significant institutional stakeholder.

Revenue model

Mosaic Immunoengineering has no commercial revenue as of the 10-K filed April 15, 2026. The company is pre-revenue and relies on external financing, including convertible notes, to fund operations.

Products and services

No approved products or commercial product candidates are disclosed in the filing excerpts. The company intends to identify and license or acquire biological product candidates for clinical development, subject to raising sufficient capital.

Customers and end markets

No commercial customers or end markets are identified in the filing excerpts. The company targets the biopharmaceutical drug development market, with potential end markets in oncology or immunology implied by the company name and Oncotelic relationship, though no specific therapeutic area is confirmed in the excerpts.

Value-chain role

Mosaic occupies an early-stage drug development role, positioned upstream of clinical testing and commercialization. It has no internal manufacturing and would contract out production to CDMOs. Technology licensing relationships include Case Western Reserve University as a preferred stockholder.

Geographic exposure

The filing references regulatory requirements in both the United States (FDA) and foreign jurisdictions, but no specific geographic operating footprint or revenue mix is disclosed.

Source: SEC 10-K, filed 2026-04-15

Industry: Biological Products, (No Diagnostic Substances) Peers: NVIDIA Corp Global Innovative Platforms Inc EMAGIN CORP Peraso Inc NanoFlex Power Corp Datavault AI Inc SPI Energy Co., Ltd. Solitron Devices Inc